Tenders/Package No. 5 Mepolizumab B 156
Awarded🇵🇱PolandSupplies

Package No. 5 Mepolizumab B 156

Auto-translated from Polish
Original title: Pakiet nr 5 Mepolizumab B 156
Szpital Specjalistyczny w Zabrzu Sp. z o.o.
Published: Sep 9, 2026
Updated: Sep 12, 2026
Source: TED - Tenders Electronic Daily (EU)

About This Opportunity

This is a supplies contract in the health and medical services sector. Located in Poland, Europe, this opportunity is open to firms and consortiums, with an estimated budget of PLN 702,780.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.

Description

Auto-translated from Polish
Package No. 5 Mepolizumab B 156. The detailed description of the subject of the order is Annex No. 3 to the SWZ – Assortment and Price Form. In accordance with Chapter III, point 3 of the SWZ: Subjective requirements for contractors - Contractors submitting an offer in the proceedings declare that they undertake to comply with the following requirements: 1) They will offer medicinal products that meet the requirements specified in the Act of September 6, 2001, Pharmaceutical Law (Journal of Laws 2026.612 consolidated text of 2026.05.07), consistent with the description of the subject of the order contained in the Assortment and Price Forms constituting Annex No. 3 to the SWZ. 2) The contractor possesses documents confirming that the products listed in the Assortment and Price Forms constituting Annex No. 3 to the SWZ are registered with the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in accordance with the requirements of the Act of 06.09.2001 Pharmaceutical Law (Journal of Laws 2026.612 consolidated text of 2026.05.07). 3) For medicines in all packages 1-30, the Ordering Party requires a valid permit from the Chief Pharmaceutical Inspectorate for trading in medicinal products. 4) Packages 1-30 contain biological medicines for treatment programs. The Ordering Party requires that the medicines are approved for use and reimbursed under treatment programs. Currently, these are: 03.0000.331.02 (B31) Treatment of pulmonary arterial hypertension 03.0000.347.02 (B47) Treatment of moderate to severe plaque psoriasis 03.0000.407.02 (B 107) Treatment of chronic spontaneous urticaria 03.0000.556.02 (B156) Treatment of patients with rhinosinusitis with nasal polyps 03.0000.424.02 (B.124) Treatment of patients with severe atopic dermatitis 03.0000.374.02 (B74) Treatment of chronic thromboembolic pulmonary hypertension (CTEPH) 03.0000.401.02 (B 101) Treatment of familial hypercholesterolemia The Ordering Party further requires that: A. The entire assortment consists of medicinal products. B. The contractor will sign annexes to the agreements if the reimbursement during the term of the agreement changes for products (with the same international name) that will be covered by such reimbursement. C. The price of the medicine, in the case of a medicine subject to an official price, must be consistent with the current official price of that medicine on the day of order fulfillment throughout the entire duration of the agreement. In the event of changes in the financing rules for the purchase of medicines by the National Health Fund that reduce prices, or a reduction in the official price of the medicine below the price resulting from the contractor's offer, an annex will be signed for the period of their validity. After this period, the price will revert to the price resulting from the contractor's original tender offer, which is the maximum price for the Ordering Party at all times. D. Transport of the product will be to the place indicated by the Ordering Party in accordance with the requirements set out in the SmPC of the medicinal products. E. The contractor will provide the Summary of Product Characteristics (SmPC) or its equivalent translation into Polish (PACKAGES 1-30) with the offer. 5) The contractor will ensure, at their own cost and risk, the transport of medicinal products to the place indicated by the Ordering Party. The transport of all medicinal products will be carried out in accordance with the requirements set out in the current documents confirming the authorization for trading and use of the subject of the order in accordance with the Act of September 6, 2001 Pharmaceutical Law (Journal of Laws 2026.612 consolidated text of 2026.05.07) and the Regulation of the Minister of Health of October 22, 2022 on the basic conditions for running a pharmacy (Journal of Laws 2025.1579) as amended by the Regulation of the Minister of Health of November 17, 2025 amending the regulation on the basic conditions for running a pharmacy. The Ordering Party has the right to inspect the means of transport used for transporting medicinal products for the presence of records of the temperature in the transport chamber, and for the presence of pallets on which boxes with medicinal products are transported. In case of non-compliance with the transport requirements specified in the current documents confirming the authorization...

Data provenance

This notice is sourced from TED - Tenders Electronic Daily (EU) and was originally published on September 9, 2026. Last refreshed 67 days ago. Original language: Polish. BidsFactory mirrors official procurement notices and links back to the source for full legal text.

About Szpital Specjalistyczny w Zabrzu Sp. z o.o.

Szpital Specjalistyczny w Zabrzu Sp. z o.o. has issued 18 procurement notices on BidsFactory, including 0 currently open and 10 awarded contracts. Activity concentrates in Health & Medical and General Supplies & Services. All notices are published for Poland. Notices are distributed via TED - Tenders Electronic Daily (EU). Most recent publication: November 3, 2026.

Frequently asked questions about this tender

Where will the contract be performed?

The contract is for delivery in Poland. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.

How can I submit a bid?

Visit TED - Tenders Electronic Daily (EU) to access the full notice, required documents, and submission instructions provided by the contracting authority.

Is this tender still open?

No — the contract has already been awarded to GSK Services Spółka z o.o.; Janssen-Cilag Polska Sp. z o.o.; Abbvie Sp. z o.o.; Komtur Polska Sp. z o. o.; Amgen Sp. z o.o.. The award notice is archived on BidsFactory for transparency and market intelligence.

Who is the contracting authority?

This notice was issued by Szpital Specjalistyczny w Zabrzu Sp. z o.o. in Poland. The authority is responsible for evaluating bids, awarding the contract, and managing performance.

What type of contract is this?

This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.

How much was the contract awarded for?

GSK Services Spółka z o.o.; Janssen-Cilag Polska Sp. z o.o.; Abbvie Sp. z o.o.; Komtur Polska Sp. z o. o.; Amgen Sp. z o.o. was awarded the contract for PLN 18,204,649. The figure reflects the value disclosed by the contracting authority in the award notice.

Find tenders like this automatically

Premium shows the full details of every tender like this one and alerts you instantly when a new one is published.

See plans

Sectors & Categories

Key Details

Estimated Budget
PLN 702,780
Contract Type
Supplies
Eligibility
Firms / Consortiums
Language
Polish

Source

ted
TED - Tenders Electronic Daily (EU)
Public Procurement

Contracting Authority

Szpital Specjalistyczny w Zabrzu Sp. z o.o.
🇵🇱Poland